The evaluative value of Sema3C and MFN2 co-expression detected by immunohistochemistry for prognosis in hepatocellular carcinoma patients after hepatectomy
Authors feng X, Zhu K, Liu J, Chen J, tang J, Liang Y, Jin R, Liang X, Cai X
Received 14 October 2015
Accepted for publication 10 January 2016
Published 30 May 2016 Volume 2016:9 Pages 3213—3221
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ram Prasad
Peer reviewer comments 2
Editor who approved publication: Dr William Cho
Xu Feng,1,* Kelei Zhu,1,2,* Jinghua Liu,1 Jiang Chen,1 Jiacheng Tang,3 Yuelong Liang,1 Renan Jin,1 Xiao Liang,1 Xiujun Cai1,3
1Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 2Department of General Surgery, Yinzhou People’s Hospital, Ningbo, 3Key Lab of Surgery of Zhejiang Province, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China
*These authors contributed equally to this work
Background: The ability to evaluate the prognosis of hepatocellular carcinoma (HCC) following hepatectomy using biological markers is of great importance.
Materials and methods: In this study, we collected samples from 54 patients with HCC after hepatectomy. Immunohistochemistry was used to detect the expression of Sema3C and MFN2 in the HCC samples.
Results: Immunohistochemistry results showed that Sema3C and MFN2 co-expression was significantly associated with tumor size. In addition, a significant association between high Sema3C and low MFN2 levels and shorter overall survival was noted, when Sema3C and MFN2 co-expression was analyzed.
Conclusion: The results suggest that the correlative expression level of Sema3C and MFN2 has a strong value in the prognosis of patients with HCC following hepatectomy.
Keywords: Sema3C, MFN2, hepatocellular carcinoma (HCC), prognosis, survival analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]